Body composition changes and satisfaction associated with gender-affirming hormone therapy in transgender men

Hoyos Emilia Gomez; Martin David Primo; Garcia Esther Delgado; Asensio Lucia Estevez; Buigues Ana Ortola; Lopez Gomez Juan Jose; Maniega Rubio Maria Antonia; Fernandez Carmen Rodriguez; Bartolome Albistegui Maria Jose; Luis Roman Daniel De

doi:10.1530/endoabs.99.EP458

EP458

Prev Next

Section Contents Cite

Endocrine Abstracts (2024) 99 EP458 | DOI: 10.1530/endoabs.99.EP458

ECE2024 Eposter Presentations Reproductive and Developmental Endocrinology (78 abstracts)

Body composition changes and satisfaction associated with gender-affirming hormone therapy in transgender men

Emilia Gomez Hoyos ¹ , David Primo Martin ¹ , Esther Delgado Garcia ¹ , Lucia Estevez Asensio ¹ , Ana Ortolá Buigues ¹ , Juan Jose Lopez Gomez ¹ , Maria Antonia Maniega Rubio ² , Carmen Rodriguez Fernandez ² , Maria Jose Bartolome Albistegui ³ & Daniel De Luis Roman ¹

Err

Author affiliations

¹Hospital Clínico Valladolid, Endocrinology and Nutrition, Valladolid, Spain; ²University Clinical Hospital of Valladolid, Mental Health, Valladolid, Spain; ³University Clinical Hospital of Valladolid, Pediatrics, Valladolid, Spain

Introduction: Gender affirming hormone therapy (GAHT) in transgender men favors their virilization. Aims: To determine its impact on body composition measured by electrical impedance and the satisfaction perceived by the subject (CRES-4 questionnaire).

Material and Methods: Prospective study in transgender men with GAHT (>2 years), attended at the Transgender Medicine Unit of the Hospital Clinico of Valladolid from January 2014 to January 2023. Recording of clinical, analytical, body composition and CRES-4 questionnaire data after giving their consent. Statistical analysis of the data by the SPSS-V17 program.

Results: 32 transgender males aged 23 [22-32] years and onset of GAHT at 18 [17-25] years with long-acting testosterone ester 2 (6.3%), short-acting 26 (81.3%) and testosterone gel 4 (12.5%). The initial BMI was 21.9 [19.6-24.7] kg/m², fat-free mass (FFM) 43.9 [40.8-47.4] kg, fat mass (FM) 15.6 [10.6-22.9] kg and estimated muscle mass (EMM) 29 [24.7-31.9] kg. At 2 years with testosterone, there was 0.82 [0.1-1.9] kg/m² increase in BMI, 3.4[2-5] kg in FFM and 3.8 [1.7-8.1] kg in EMM. FM decreased -1.7[-3.3 to 1] kg. 21/22 subjects were satisfied with GAHT, with 255 [242-265] points on CRES-4. Serum testosterone (near the end of the dose interval) was 391 [264-817] ng/dl with 17 (53%) in the low range (</=400 ng/dl) and 15 (47%) subjects in the mid-high range of normal (>400 ng/dl). In both groups, changes in BMI (P=0.723), in FFM (P=0.288) and in FM (P=0.288) were similar. However, the increase in EMM was 4.9[2.8-10] kg in the low range and 3.3[1.2-7.1] kg in the mid-high range (P=0.077). CRES-4 score in the low range was 262 [250-275] and in the mid- high range 255 [242-262] points (p 0.273).

Conclusion: GAHT-induced body composition changes in transgender males were satisfactory. Even with testosterone levels near the end of the dosing interval in the low normal range.